Evidence map›Paper›PMID 39795882›Full record

ArticleInternational journal of molecular sciences2024

Novel

Barbara Anna Bokor, Aliasgari Abdolreza, Flóra Kaptás, Margit Pál, Zita Battyani, Márta Széll, Nikoletta Nagy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Barbara Anna BokorDepartment of Medical Genetics, University of Szeged, 6720 Szeged, Hungary.
Aliasgari AbdolrezaDepartment of Medical Genetics, University of Szeged, 6720 Szeged, Hungary.
Flóra KaptásDepartment of Medical Genetics, University of Szeged, 6720 Szeged, Hungary.ORCID 0000-0003-1997-1213
Margit PálDepartment of Medical Genetics, University of Szeged, 6720 Szeged, Hungary.ORCID 0000-0003-3662-0837
Zita BattyaniMór Kaposi Teaching Hospital, 7400 Kaposvár, Hungary.
Márta SzéllDepartment of Medical Genetics, University of Szeged, 6720 Szeged, Hungary.
Nikoletta NagyDepartment of Medical Genetics, University of Szeged, 6720 Szeged, Hungary.ORCID 0000-0001-8576-7953

Funding

Hungarian Government EFOP-3.6.1-16-2016-00008 and GINOP-2.3.2-15-2016-00039
6 · The paper itself

Abstract

Accumulating evidence suggests that inherited melanoma is not rare and approx. one in seven individuals with melanoma has clinically relevant hereditable cancer-predisposing and/or -susceptibility variant(s). Concerning its germline genetic background, genetic screening aims to identify either variants of predisposing genes with high penetrance or variants of susceptibility genes with medium or low penetrance. However, less attention is paid to genetic testing of germline variants of genes influencing patients' survival outcomes or enhancing the design of new therapies. We aimed to investigate whether the germline genetic background of a Hungarian melanoma cohort (

Indexed as

DNA HelicasesFanconi Anemia Complementation Group ProteinsMelanomaNuclear ProteinsSkin NeoplasmsAdultAgedCohort StudiesFemaleGenetic Predisposition to DiseaseGerm-Line MutationHumansHungaryMaleMiddle AgedPrognosisDNA HelicasesFANCI protein, humanFanconi Anemia Complementation Group ProteinsNuclear ProteinsRAD54B protein, humangermlinelikely pathogenic variantmelanomanovel variantpatients’ survivalprogressiontherapy resistance

Identifiers

PMID39795882
PMCPMC11719457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.